Results 241 to 250 of about 114,325,321 (319)

Pyridyl‐Thiazole‐Thiosemicarbazones as Antitrypanosomatidae Agents: Design, Synthesis, and In Silico Profiling

open access: yesChemMedChem, Volume 21, Issue 16, 27 August 2026.
A novel pyridine–thiazole derivative, Compound 8, exhibited potent dual antitrypanosomatid activity. It demonstrated remarkable in vitro efficacy against Trypanosoma cruzi (IC50 = 1.0 µM) and L. amazonensis (IC50 = 3.9 µM). Molecular docking studies suggested interactions with heme and multiple molecular targets.
Anderson José Firmino Santos da Silva   +10 more
wiley   +1 more source

Exploring Disulfide Bridge as a Tool to Improve Pioglitazone’s Neuroprotective Potential: Toward the Development of Prolonged‐Acting MAO‐B/PPARγ Modulators

open access: yesChemMedChem, Volume 21, Issue 15, 14 August 2026.
Pioglitazone is an antidiabetic drug acting as a peroxisome proliferator‐activated receptor γ (PPARγ) agonist and later repositioned as a monoamine oxidase B (MAO‐B) inhibitor. Despite promising preclinical premises, it showed a lack of efficacy in clinical trials as a treatment for neurodegenerative diseases.
Filippo Basagni   +12 more
wiley   +1 more source

Could Fabry Disease Cause Giant Coronary Aneurysms in a 7-Month-Old Infant: A Case Report. [PDF]

open access: yesClin Case Rep
Shabanian R   +5 more
europepmc   +1 more source

Diagnostic and therapeutic applications of the glycan biomarker H3N2b in GM1 Gangliosidosis. [PDF]

open access: yesMol Genet Metab
Kell P   +14 more
europepmc   +1 more source

Automated quantification of skin Gb3 load and white matter lesion assessment in Fabry disease. [PDF]

open access: yesOrphanet J Rare Dis
Pfister C   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy